|Mr. Sean McClain||Founder, CEO, Pres & Director||1.02M||N/A||1991|
|Dr. Sarah Korman J.D., Ph.D.||Chief Legal Officer & Corp. Sec.||591.47k||N/A||1979|
|Mr. Gregory T. Schiffman CPA, CPA, MBA||Chief Financial Officer||N/A||N/A||1957|
|Todd Bedrick CPA||Sr. VP & Chief Accounting Officer||N/A||N/A||N/A|
|Mr. Jack Gold||Chief Marketing Officer||N/A||N/A||N/A|
|Melissa Patterson Ph.D.||Chief of Staff||N/A||N/A||N/A|
|Ms. Denise Dettore||Chief People Officer||N/A||N/A||N/A|
|Dr. Andreas Busch Ph.D.||Chief Innovation Officer||N/A||N/A||1963|
|Jonathan Eads M.S.||Sr. VP of Informatics||N/A||N/A||N/A|
|Thomas Wrona J.D., Ph.D.||Sr. VP of Intellectual Property||N/A||N/A||N/A|
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation’s ISS Governance QualityScore as of November 28, 2022 is 9. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 8.